Skip to main content

NeuroSense Therapeutics Ltd.

corporate_fare Company Profile

NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed NRSN - Latest Insights

NRSN
Apr 28, 2026, 3:38 PM EDT
Filing Type: 6-K
Importance Score:
9
NRSN
Apr 06, 2026, 9:20 AM EDT
Filing Type: 6-K
Importance Score:
7
NRSN
Apr 03, 2026, 9:27 AM EDT
Filing Type: 6-K
Importance Score:
9
NRSN
Mar 31, 2026, 9:29 AM EDT
Filing Type: 20-F
Importance Score:
9
NRSN
Mar 31, 2026, 9:20 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
NRSN
Mar 24, 2026, 10:11 AM EDT
Filing Type: 6-K
Importance Score:
8
NRSN
Mar 16, 2026, 12:27 PM EDT
Filing Type: 6-K
Importance Score:
9
NRSN
Feb 18, 2026, 9:21 AM EST
Filing Type: 6-K
Importance Score:
9
NRSN
Feb 13, 2026, 4:35 PM EST
Filing Type: 6-K
Importance Score:
8
NRSN
Feb 09, 2026, 9:30 AM EST
Filing Type: 6-K
Importance Score:
7
NRSN
Jan 29, 2026, 5:28 PM EST
Filing Type: F-3
Importance Score:
8